news, journals and articles from all over the world.
A $15 million gift to Harvard Medical School from the Bertarelli Foundation is boosting efforts to understand and combat rare cancers. Nine teams across the school and its affiliated hospitals describe their efforts to illuminate understudied malignancies.
Read moreCLEVELAND: As part of the new Cleveland Innovation District announced today by State of Ohio Governor Mike DeWine, Lieutenant Governor Jon Husted, JobsOhio and Ohio Development Services Agency, Cleveland Clinic will significantly expand its global commitment to infectious disease research and translational programs to form the Global Center for Pathogen Research & Human Health.
The new Center will position Ohio as an international leader for research into emerging pathogens and virus-related diseases and will serve as a significant economic catalyst in Northeast Ohio. Funding comes through a $500 million investment from the State of Ohio, JobsOhio and Cleveland Clinic.
the National Institutes of Health has renewed a Center of Biomedical Research Excellence (COBRE) grant at the University of Delaware. The COBRE research team is focused on discovery of new molecules that can be used to study and treat diseases such as breast cancer, renal cancer, Crohn’s disease, tuberculosis and Legionnaires disease.
Read moreThe Endocrine Society—the world’s largest professional organization for endocrine scientists and physicians—is calling on Congress to pass the House Labor-HHS spending bill to ensure health agencies are funded before the start of Fiscal Year 2021 and to avoid the tumult and disruption of a continuing resolution and potential government shutdowns.
Read more
The COVID-19 pandemic demands action on many fronts, from prevention to testing to treatment. Not content to focus its research efforts on just one, the laboratory of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University is tackling the problem from seven different angles.
Read more
The researchers discovered that encapsulating ellagic acid in chitosan, a sugar, reduces its inherent cytotoxicity while enhancing its anti-oxidant properties. The chitosan shell, which makes up the hard outer skeleton of shellfish, also permits EA delivery via a rapid burst phase and a relatively slow phase.
Read more
Francis Collins, M.D., Ph.D., director of the NIH, flew to Birmingham on Thursday, March 5, to start a long-anticipated visit to UAB. Collins soon learned he had a problem back home. Maryland public health officials were reporting the first two cases of COVID-19 in the county where the NIH sits.
Read moreA protein known to help cells defend against infection also regulates the form and function of mitochondria, according to a new paper in Nature Communications.
Read more
Wistar and Leiden University Medical Center (LUMC) formalized a memorandum of understanding between the two institutions to explore a postdoctoral training exchange program in immunology, cancer research and vaccine biology. The Wistar-Schoemaker International Postdoctoral Fellowship would bring recent Ph.D. graduates trained at LUMC to Wistar to advance their research education under the mentorship of cutting-edge biomedical research leaders.
Read more
Anna Goodroe, D.V.M., DACLAM, is the newest veterinarian to join the staff at the Southwest National Primate Research Center on the Texas Biomedical Research Institute campus. As an Assistant Veterinarian, she is part of the Veterinary Resources and Research Support team.
Read moreThe Congress of Neurological Surgeons Foundation (CNS Foundation) announced a second K12 award will be funded by a generous gift from the Congress of Neurological Surgeons (CNS). The award is made possible through a collaboration with the Foundation of the National Institutes of Health (FNIH) and the National Institutes of Health (NIH).
Read more
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).
Read more